Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiodynamic Therapy With 5-ALA in Recurrent Glioblastoma
NCT05590689Phase 2Recruiting
- Sponsor
- Universität Münster
- Start
- Nov 2022
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by Universität Münster. Started Nov 2022; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05590689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590689.